Cristian Massacesi

Executive vice president, chief medical officer and head of development at Bristol Myers Squibb

Appears in 1 story

Stories

Bristol Myers lung drug succeeds at low dose, misses at high dose

Leading the company's response to the ALOFT-IPF results

Bristol Myers Squibb's experimental lung disease drug admilparant met its main goal in a late-stage trial, but only at the lower of two tested doses. The 60 milligram dose significantly slowed the decline in lung function among patients with idiopathic pulmonary fibrosis, while the 120 milligram dose missed the statistical threshold.

Updated 2 hours ago